Authors
Latest:
Bigger than Brand: Portfolio Positioning for PharmaJenna Earl outlines the three most important things to understand about portfolio positioning in pharma.
Latest:
The Path To Market Access: Winning Strategies To Build Value With PayersSuccess in today’s rapidly changing market access world depends on understanding your product’s value through the eyes of payers and shaping crucial value communication around the needs of market access stakeholders as much as it does on developing solid evidence of the value of your product.
Latest:
Pushback on Rare Drug Prices: Not So Rare After AllRare Disease Day is a good moment to sound a warning that providers of rare medicines may be the next to land in the hot seat, writes Meg Alexander.
Latest:
The NHS Training Budget Requires More Than Just a Band-AidThe UK's National Health Services needs to rethink the ‘sticking plaster’ solution of training replacement staff, writes James Brook.
Latest:
A New Era in Precision Gene EditingMedicine is entering a new era of “gene editing.” Instead of simply being able to “read” our genes, practitioners will be able to adapt and modify DNA sequencing in living cells to treat, cure, and even prevent disease. Defective genes responsible for life-threatening diseases can be rendered harmless by gene editing; it can also be used to develop new, precisely targeted biological drugs based on an individual’s distinct genetic markers. The full list of possibilities, in every area of the life sciences, is simply beyond imagination.
Latest:
A New Era in Precision Gene EditingMedicine is entering a new era of “gene editing.” Instead of simply being able to “read” our genes, practitioners will be able to adapt and modify DNA sequencing in living cells to treat, cure, and even prevent disease. Defective genes responsible for life-threatening diseases can be rendered harmless by gene editing; it can also be used to develop new, precisely targeted biological drugs based on an individual’s distinct genetic markers. The full list of possibilities, in every area of the life sciences, is simply beyond imagination.
Latest:
Precision Medicine's March to Market: 'Pairing' for SuccessIn the past few years, we’ve seen the biopharmaceutical industry begin to shift from a one-size-fits-all blockbuster approach toward an individualized, precision science model. This transformation has propelled companion diagnostics (CDx) into playing a more critical role than ever in the commercialization of biopharmaceutical therapeutics.
Latest:
Think Globally, Act LocallyThe best approach to getting global brand campaigns to work all over the world
Latest:
Think Globally, Act LocallyThe best approach to getting global brand campaigns to work all over the world
Latest:
Market Access ReinventedThe key steps to implementing the "patient access" model of the future
Latest:
Market Access ReinventedThe key steps to implementing the "patient access" model of the future
Latest:
Barrier to Generic Competition Threatens Safe, Low Cost Drug OptionsCarlos Angulo and Alexandra W. “Sasha” Miller argue that an increasingly common brand company tactic is threatening to undermine the entire FDA generic drug approval process.
Latest:
The 'Prosolidate' Push: New Agency Service MixThe advantages for brand teams in leveraging independent agencies in their campaigns.
Latest:
Precision Medicine's March to Market: 'Pairing' for SuccessIn the past few years, we’ve seen the biopharmaceutical industry begin to shift from a one-size-fits-all blockbuster approach toward an individualized, precision science model. This transformation has propelled companion diagnostics (CDx) into playing a more critical role than ever in the commercialization of biopharmaceutical therapeutics.
Latest:
Precision Medicine's March to Market: 'Pairing' for SuccessIn the past few years, we’ve seen the biopharmaceutical industry begin to shift from a one-size-fits-all blockbuster approach toward an individualized, precision science model. This transformation has propelled companion diagnostics (CDx) into playing a more critical role than ever in the commercialization of biopharmaceutical therapeutics.
Latest:
What Lessons Can the World Learn from Ebola?Ebola showed that when innovation is truly integrated, we can enter into unknown territories and bring new innovations with us, writes Neil Saward.
Latest:
The Emergence of Commercial Health Insurances as an Access Route to the Chinese MarketCommercial Health Insurance may bring more opportunities for market access in China.
Latest:
Europe Under Pressure: Gearing Up for a Year of Regulatory ConvergenceIn the last year regulatory authorities sharpened their focus on gathering more data and on achieving transparency and harmonization. Erick Gaussens reviews 2015 and looks at companies’ need to respond to converging demands in 2016.
Latest:
Seeing Through Physicians' Eyes: Three Priorities for PharmaPhysicians who show true empathy for their patients tend to have better outcomes. Their patients stick to treatment plans, heal faster, and have fewer hospital readmissions. The same principle applies to pharma companies trying to market to physicians, write Pratap Khedkar and Malcolm Sturgis.
Latest:
The Healing Art in MedicinePharm Exec talks with David Dosa, a leading physician in geriatric medicine, whose famous work with a cat named oscar in end-of-life diagnostics became the stuff of therapeutic legend.
Latest:
From 1990s Business Wisdom to Today’s BioPharma SuccessApplying the McKinsey 7S Framework to TLL and regional marketing teams.
Latest:
Marketing Curative Therapies: Are We Ready?The eight trends brought on by “once-and-done” interventions that may transform thinking around healthcare marketing.
Latest:
Emergency Disaster Response: Three Ways Pharmas Can HelpAs vital contributors to hospital disaster preparedness, the pharma industry has a role to play in making sure medical networks have what they need to meet the unforeseen, including future disasters.
Latest:
The Creative Impulse: Defending Pharma and Health DTCDefending pharma and health direct-to-consumer advertising is a top 2016 priority for the 4A’s industry trade group.
Latest:
Access to Orphan Drugs in TurkeyGülce Belgin and Donald Macarthur explore the options available for companies to meet the needs of the rare disease population in Turkey.
Latest:
Sales & Marketing: Reaching the UnreachablesThe traditional commercial sales model in biopharma of deploying teams of reps to call on physicians is broken. Here, Stephen J. Donnelly outlines a new approach.
